FY2028 Earnings Forecast for TNDM Issued By Leerink Partnrs

Tandem Diabetes Care, Inc. (NASDAQ:TNDM - Free Report) - Equities research analysts at Leerink Partnrs upped their FY2028 earnings per share estimates for Tandem Diabetes Care in a research note issued on Wednesday, April 30th. Leerink Partnrs analyst M. Kratky now forecasts that the medical device company will post earnings per share of $0.42 for the year, up from their previous forecast of $0.31. The consensus estimate for Tandem Diabetes Care's current full-year earnings is ($1.68) per share. Leerink Partnrs also issued estimates for Tandem Diabetes Care's FY2029 earnings at $0.88 EPS.

Tandem Diabetes Care (NASDAQ:TNDM - Get Free Report) last released its earnings results on Wednesday, April 30th. The medical device company reported ($0.67) earnings per share for the quarter, missing the consensus estimate of ($0.60) by ($0.07). The firm had revenue of $234.42 million during the quarter, compared to analyst estimates of $220.19 million. Tandem Diabetes Care had a negative net margin of 14.84% and a negative return on equity of 44.19%. The business's revenue was up 22.3% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.65) earnings per share.

A number of other research analysts have also recently weighed in on the company. Wells Fargo & Company reduced their target price on Tandem Diabetes Care from $22.00 to $20.00 and set an "equal weight" rating on the stock in a report on Thursday, May 1st. Sanford C. Bernstein cut Tandem Diabetes Care from an "outperform" rating to a "market perform" rating and reduced their price objective for the stock from $35.00 to $25.00 in a research note on Friday, February 28th. Barclays lowered their target price on shares of Tandem Diabetes Care from $60.00 to $53.00 and set an "overweight" rating for the company in a research note on Friday, February 28th. Piper Sandler lowered their price objective on shares of Tandem Diabetes Care from $36.00 to $30.00 and set an "overweight" rating for the company in a research report on Thursday, May 1st. Finally, Stifel Nicolaus dropped their target price on Tandem Diabetes Care from $60.00 to $31.00 and set a "buy" rating on the stock in a report on Thursday, May 1st. Eight research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company's stock. According to data from MarketBeat, Tandem Diabetes Care currently has a consensus rating of "Moderate Buy" and an average price target of $39.81.

Tandem Diabetes Care Price Performance

Shares of TNDM stock traded up $0.52 during trading hours on Friday, hitting $21.84. The company's stock had a trading volume of 471,627 shares, compared to its average volume of 1,497,516. The company has a current ratio of 2.90, a quick ratio of 2.32 and a debt-to-equity ratio of 1.29. Tandem Diabetes Care has a twelve month low of $15.75 and a twelve month high of $53.69. The business has a fifty day moving average of $18.55 and a 200-day moving average of $28.38. The stock has a market cap of $1.45 billion, a price-to-earnings ratio of -11.34 and a beta of 1.47.

Insiders Place Their Bets

In related news, COO Jean-Claude Kyrillos purchased 10,538 shares of the company's stock in a transaction dated Friday, March 7th. The shares were acquired at an average cost of $18.12 per share, with a total value of $190,948.56. Following the completion of the purchase, the chief operating officer now owns 10,538 shares of the company's stock, valued at $190,948.56. The trade was a ∞ increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 1.90% of the company's stock.

Institutional Investors Weigh In On Tandem Diabetes Care

Several institutional investors have recently made changes to their positions in the company. Vanguard Group Inc. raised its position in shares of Tandem Diabetes Care by 1.1% in the fourth quarter. Vanguard Group Inc. now owns 7,440,005 shares of the medical device company's stock valued at $267,989,000 after purchasing an additional 77,451 shares during the period. GW&K Investment Management LLC increased its holdings in shares of Tandem Diabetes Care by 34.9% during the 1st quarter. GW&K Investment Management LLC now owns 2,863,987 shares of the medical device company's stock worth $54,874,000 after purchasing an additional 740,499 shares during the period. ArrowMark Colorado Holdings LLC raised its position in shares of Tandem Diabetes Care by 14.1% during the fourth quarter. ArrowMark Colorado Holdings LLC now owns 2,723,715 shares of the medical device company's stock valued at $98,108,000 after buying an additional 337,026 shares during the last quarter. Stephens Investment Management Group LLC lifted its stake in shares of Tandem Diabetes Care by 9.7% in the first quarter. Stephens Investment Management Group LLC now owns 1,706,915 shares of the medical device company's stock valued at $32,704,000 after buying an additional 151,106 shares during the period. Finally, Jacobs Levy Equity Management Inc. increased its stake in Tandem Diabetes Care by 189.0% during the fourth quarter. Jacobs Levy Equity Management Inc. now owns 1,661,013 shares of the medical device company's stock valued at $59,830,000 after acquiring an additional 1,086,337 shares during the period.

Tandem Diabetes Care Company Profile

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.